Therapeutic agent for dystrophic epidermolysis bullosa

The present disclosure pertains to a composition to be used in treating dystrophic epidermolysis bullosa, said composition containing, for example, bulla-derived cells of a dystrophic epidermolysis bullosa patient that have been genetically engineered so as to produce type VII collagen.

Saved in:
Bibliographic Details
Main Authors TAMAI, Katsuto, TAMAKOSHI, Tomoki, KIKUCHI, Yasushi
Format Patent
LanguageEnglish
Published 16.03.2023
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present disclosure pertains to a composition to be used in treating dystrophic epidermolysis bullosa, said composition containing, for example, bulla-derived cells of a dystrophic epidermolysis bullosa patient that have been genetically engineered so as to produce type VII collagen.
Bibliography:Application Number: AU20200459825